Clinical Trial Update: A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLC [Phase 3]

View source ↗

Summary

A Phase 3 prospective cohort study is evaluating neoadjuvant chemotherapy plus Sintillumab for resectable non-small cell lung cancer. The trial is currently NOT…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Sintillumab

Snippet

Sponsor: Tang-Du Hospital | Conditions: Resectable Non-small Cell Lung Cancer | Phase 3 | Status: NOT_YET_RECRUITING